1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Press Releases
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  05/25 11:35:02 am EDT
51.26 EUR   -0.58%
05/24Galapagos In-Licenses Drug Targets for Inflammatory Bowel Disease From Scipher
MT
05/20Intervest Offices & Warehouses Extends Lease Deals For Office Portfolio In Belgium
MT
05/09RBC Raises Price Target on Galapagos to $62 From $60, Maintains Sector Perform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société GALAPAGOS NV
05/06Galapagos creates new subscription right plans
GL
05/06Galapagos creates new subscription right plans
AQ
05/05Galapagos demonstrates regulatory and commercial progress in Q1 2022
GL
04/27GALAPAGOS : announces appointment of Dr. Paul Stoffels as Chairman of the board - Form 6-K
PU
04/26Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
GL
04/11SUBJECT : Galapagos AGM/EGM 2022 April 11th, 2022 - Form 6-K
PU
04/11GALAPAGOS : Chairman letter to shareholders
PU
04/01GALAPAGOS : Glpg egm & agm 2022
PU
03/28Jyseleca® approved in Japan for ulcerative colitis
AQ
03/25GALAPAGOS : — Proposal of one-tier board structure & appointment of three new directo..
PU
03/24GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
03/24CORRECTION : Galapagos publishes 2021 annual report and announces extraordinary and annual..
GL
03/24Galapagos publishes 2021 annual report and announces extraordinary and annual sharehold..
AQ
03/24GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
03/18Galapagos increases share capital through subscription right exercises
AQ
02/24GALAPAGOS : 2021 results set stage for future growth - Form 6-K
PU
02/24Galapagos 2021 results set stage for future growth
GL
02/07GALAPAGOS : provides further insights into the treatment of ulcerative colitis at the Euro..
PU
02/07GALAPAGOS : receives transparency notification from EcoR1 Capital - Form 6-K
PU
02/03Galapagos receives transparency notification from EcoR1 Capital
AQ
02/02Galapagos provides further insights into the treatment of ulcerative colitis at the Eur..
AQ
01/27GALAPAGOS : appoints Paul Stoffels as Chief Executive Officer - Form 6-K
PU
01/26GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/26Galapagos creates new subscription right plan
AQ
01/26Galapagos appoints Paul Stoffels as Chief Executive Officer
AQ
01/19GALAPAGOS : JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WIT..
PU
01/18Jyseleca®▼ (filgotinib) licensed for the treatment of adult patients with moderat..
AQ
01/13GALAPAGOS : creates new subscription right plan - Form 6-K
PU
01/13Galapagos creates new subscription right plan
AQ
01/10GALAPAGOS : to present at 40th Annual J.P. Morgan Healthcare Conference - Form 6-K
PU
01/06Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
AQ
2021GALAPAGOS : increases share capital through subscription right exercises - Form 6-K
PU
2021Galapagos increases share capital through subscription right exercises
GL
2021Galapagos increases share capital through subscription right exercises
GL
2021GALAPAGOS : completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in poly..
PU
2021Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in pol..
AQ
2021GALAPAGOS : Jyseleca®▼(filgotinib) approved in the European Union for the treatment ..
PU
2021Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcera..
GL
2021Galapagos reports commercial and operational progress at Q3 financial results - Form 6-..
PU
2021Galapagos reports commercial and operational progress at Q3 financial results
AQ
2021GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
PU
2021GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
PU
2021GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga..
AQ
2021GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi..
AQ
2021GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
2021GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises
PU
2021GALAPAGOS : increases share capital through subscription right exercises
AQ
2021GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT O..
PU
2021GALAPAGOS : N.v., - galapagos announces positive chmp opinion for jyseleca® (filgotinib) f..
PU
2021GALAPAGOS : Announces positive chmp opinion for jyseleca® (filgotinib) for the treatment o..
AQ
2021GALAPAGOS NV : - Bionity - Galapagos announces planned retirement of CEO
AQ
2021GALAPAGOS : announces planned retirement of CEO (Form 6-K)
PU
2021GALAPAGOS : announces planned retirement of CEO
AQ
2021GALAPAGOS : reports H1 financial results with refocused pipeline and operational progress
AQ
2021GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TYK2 inhibit..
PU
2021GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition ..
PU
2021GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation (F..
PU
2021GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
PU
2021GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation
AQ
2021GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha..
AQ
2021GALAPAGOS : announces new data supporting rapid symptom improvement and sustained steroid-..
AQ
2021GALAPAGOS : announces departure of CSO Piet Wigerinck later this year (Form 6-K)
PU
2021GALAPAGOS : increases share capital through subscription right exercises (Form 6-K)
PU
2021Galapagos increases share capital through subscription right exercises
GL
2021GALAPAGOS : SELECTION study on filgotinib in ulcerative colitis published in The Lancet (F..
PU
2021GALAPAGOS : to present data on rheumatoid arthritis at the upcoming European League Agains..
PU
2021GALAPAGOS : announces first patient enrolled in FILOSOPHY study to advance understanding o..
PU
2021Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding ..
GL
2021GALAPAGOS : refocuses pipeline and rightsizes operations (Form 6-K)
PU
2021GALAPAGOS : Transparency notification received from The Capital Group
AQ
2021GALAPAGOS : creates new subscription right plans
PU
2021GALAPAGOS : Written questions and answers
PU
2021GALAPAGOS : Extension of lock-up period in Gilead-Galapagos collaboration agreement
AQ
2021GALAPAGOS NV : - Publication of the annual report and invitation to the ordinary sharehold..
AQ
2021GALAPAGOS : Statutory auditor's report on the non-consolidated financial statements per 31..
PU
1  2  3  4  5  6  7Next
Official Publications
05/06Press Release 
05/051st quarter report 
05/051st quarter report 
04/26Nomination 
03/24Report 
03/24Report 
Upcoming event on GALAPAGOS NV